Summary

Global Obsessive-Compulsive Disorder Drugs Market was valued at USD 882.50 million in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 7.60% through 2030. An anxiety illness known as obsessive-compulsive disorder (OCD) is characterized by irrational and uncontrolled thoughts and concerns that drive a person to engage in repetitive behavior. For instance, according to the National Comorbidity Survey Replication, 1.2% of U.S. adults had OCD in the past year, with a higher prevalence in females (1.8%) compared to males (0.5%). Obsessive-compulsive disorder is a condition that causes a person to get fixated on a certain idea or fear. Numerous further prospects in the market for OCD medications are anticipated to arise because of recent improvements in therapy, therapies, and innovative treatments as well as in anti-anxiety, antipsychotic, and antidepressant medications. However, the introduction of generic versions of branded medications and the patent expiration of patented ones are two factors anticipated to impede market development over the projection period.
Key Market Drivers
Increasing Prevalence of OCD
Increased awareness campaigns, both online and offline, have educated the public and healthcare professionals about the symptoms of OCD. As people become more informed, they are more likely to seek help and receive a diagnosis. For instance, according to a January 2022 research article, fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) approved for obsessive-compulsive disorder, has shown potential therapeutic benefits for COVID-19 based on multiple studies. This highlights its emerging role beyond mental health treatment.
Additionally, according to WHO data updated in September 2021, depression affects approximately 5% of adults globally and is the leading cause of disability worldwide. This high prevalence drives demand for antidepressants, significantly contributing to market growth as more individuals seek effective treatment options.
Advances in the understanding of OCD have led to more precise diagnostic criteria. This has enabled healthcare providers to identify OCD in individuals who might have previously been misdiagnosed or undiagnosed. Efforts to reduce the stigma associated with mental health conditions have been ongoing. As stigma decreases, individuals are more willing to talk openly about their symptoms and seek treatment without fear of discrimination. In some healthcare settings, routine mental health screenings are becoming more common. This proactive approach can lead to the identification of individuals with OCD who may not have sought help otherwise. OCD often co-occurs with other mental health disorders, such as depression and anxiety. As these comorbid conditions are better recognized and treated, individuals with OCD may also receive a diagnosis and appropriate treatment. Events such as the COVID-19 pandemic have drawn attention to mental health issues, including OCD. The pandemic's impact on mental health has led to increased recognition of OCD symptoms in affected individuals.
Key Market Challenges
Comorbid Conditions
Individuals with comorbid conditions often require more complex treatment plans. When OCD is accompanied by other psychiatric disorders like depression, anxiety, or substance abuse, healthcare providers need to consider how these conditions interact and choose medications that can effectively address multiple symptoms. This complexity can lead to challenges in finding the right combination of drugs. Polypharmacy, the use of multiple medications concurrently, may be necessary for individuals with comorbid conditions. This can increase the risk of drug interactions, adverse effects, and medication non-adherence. Healthcare providers must carefully manage medication regimens to optimize treatment outcomes. Comorbid conditions can lead to variations in treatment responses. What works well for one condition may not be as effective for another. Finding medications that are both safe and effective across multiple conditions can be a challenge. Treating individuals with comorbid conditions often involves more frequent healthcare visits, medication management, and therapy sessions. These increased healthcare costs can impact both individuals and healthcare systems, potentially affecting the demand for OCD drugs. The presence of comorbid conditions can complicate the diagnostic process. Symptoms of one condition may mask or mimic those of another, leading to potential misdiagnoses. Accurate diagnosis is essential for tailoring treatment plans. In cases of comorbidity, healthcare providers must prioritize which condition to address first. For example, if a patient has both OCD and a substance use disorder, it may be necessary to treat the substance use disorder before addressing the OCD symptoms effectively.
Key Market Trends
Stigma Reduction
Reduced stigma encourages earlier intervention, which can lead to better treatment outcomes. When individuals seek help at the onset of symptoms, their conditions may be more manageable, potentially reducing the overall duration of treatment and the need for more intensive interventions. Stigma can be a barrier to medication adherence. When individuals are more open about their mental health conditions and receive support from their social networks, they may be more likely to adhere to their treatment plans, including taking prescribed OCD medications consistently. Stigma reduction efforts can lead to increased support for mental health services, including access to psychiatrists, therapists, and medication management. This expansion of services benefits individuals seeking treatment for OCD. When individuals with OCD feel less stigmatized, they may become more empowered to actively participate in their treatment decisions. This can lead to more collaborative and effective treatment plans, including medication choices. Stigma reduction often goes hand in hand with advocacy and support efforts. Patient advocacy groups and mental health organizations play a crucial role in raising awareness, destigmatizing mental health conditions, and advocating for improved access to mental health services and treatments. As stigma diminishes, there is a greater opportunity for the integration of mental health services into primary care settings. This can improve the identification and management of mental health conditions like OCD, potentially leading to more individuals receiving treatment.
Key Market Players
• Abbott SA
• Eli Lilly, and Company
• Viatria Inc.
• H. LUNDBECK A/S,
• GlaxoSmithKline plc
• Pfizer Inc.
• Zydus Pharmaceuticals, Inc.
• Lupin Pharmaceuticals, Inc.
• Amneal Pharmaceuticals LLC
• Teva Pharmaceutical industries Ltd.
Report Scope:
In this report, the Global Obsessive-Compulsive Disorder Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Obsessive-Compulsive Disorder Drugs Market, By Type:
o SSRI (Selective Serotonin Reuptake Inhibitors)
o TCA (Tricyclic Antidepressant)
• Obsessive-Compulsive Disorder Drugs Market, By Application:
o Research Institute
o Hospitals & Clinics
o Others
• Obsessive-Compulsive Disorder Drugs Market, By region:
o North America
§ United States
§ Canada
§ Mexico
o Asia-Pacific
§ China
§ India
§ South Korea
§ Australia
§ Japan
o Europe
§ Germany
§ France
§ United Kingdom
§ Spain
§ Italy
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Obsessive-Compulsive Disorder Drugs Market.
Available Customizations:
Global Obsessive-Compulsive Disorder Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Obsessive-Compulsive Disorder Drugs Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (SSRI (Selective Serotonin Reuptake Inhibitors), TCA (Tricyclic Antidepressant))
5.2.2. By Application (Research Institute, Hospitals & Clinics, Others)
5.2.3. By Region
5.2.4. By Company (2024)
5.3. Market Map
6. Asia Pacific Obsessive-Compulsive Disorder Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Application
6.2.3. By Country
6.3. Asia Pacific: Country Analysis
6.3.1. China Obsessive-Compulsive Disorder Drugs Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Application
6.3.2. India Obsessive-Compulsive Disorder Drugs Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Application
6.3.3. Australia Obsessive-Compulsive Disorder Drugs Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Application
6.3.4. Japan Obsessive-Compulsive Disorder Drugs Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Type
6.3.4.2.2. By Application
6.3.5. South Korea Obsessive-Compulsive Disorder Drugs Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Type
6.3.5.2.2. By Application
7. Europe Obsessive-Compulsive Disorder Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Application
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. France Obsessive-Compulsive Disorder Drugs Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Application
7.3.2. Germany Obsessive-Compulsive Disorder Drugs Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Application
7.3.3. Spain Obsessive-Compulsive Disorder Drugs Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Application
7.3.4. Italy Obsessive-Compulsive Disorder Drugs Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Application
7.3.5. United Kingdom Obsessive-Compulsive Disorder Drugs Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Application
8. North America Obsessive-Compulsive Disorder Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Application
8.2.3. By Country
8.3. North America: Country Analysis
8.3.1. United States Obsessive-Compulsive Disorder Drugs Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Application
8.3.2. Mexico Obsessive-Compulsive Disorder Drugs Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Application
8.3.3. Canada Obsessive-Compulsive Disorder Drugs Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Application
9. South America Obsessive-Compulsive Disorder Drugs Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Application
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Obsessive-Compulsive Disorder Drugs Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Application
9.3.2. Argentina Obsessive-Compulsive Disorder Drugs Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Application
9.3.3. Colombia Obsessive-Compulsive Disorder Drugs Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Application
10. Middle East and Africa Obsessive-Compulsive Disorder Drugs Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Application
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Obsessive-Compulsive Disorder Drugs Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Application
10.3.2. Saudi Arabia Obsessive-Compulsive Disorder Drugs Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Application
10.3.3. UAE Obsessive-Compulsive Disorder Drugs Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Application
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. Global Obsessive-Compulsive Disorder Drugs Market: SWOT Analysis
14. Porter’s Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product
15. PESTLE Analysis
16. Competitive Landscape
16.1. Abbott SA
16.1.1. Business Overview
16.1.2. Company Snapshot
16.1.3. Products & Services
16.1.4. Financials (In case of listed companies)
16.1.5. Recent Developments
16.1.6. SWOT Analysis
16.2. Eli Lilly, and Company
16.2.1. Business Overview
16.2.2. Company Snapshot
16.2.3. Products & Services
16.2.4. Financials (In case of listed companies)
16.2.5. Recent Developments
16.2.6. SWOT Analysis
16.3. Viatria Inc.,
16.3.1. Business Overview
16.3.2. Company Snapshot
16.3.3. Products & Services
16.3.4. Financials (In case of listed companies)
16.3.5. Recent Developments
16.3.6. SWOT Analysis
16.4. H. LUNDBECK A/S
16.4.1. Business Overview
16.4.2. Company Snapshot
16.4.3. Products & Services
16.4.4. Financials (In case of listed companies)
16.4.5. Recent Developments
16.4.6. SWOT Analysis
16.5. GlaxoSmithKline plc
16.5.1. Business Overview
16.5.2. Company Snapshot
16.5.3. Products & Services
16.5.4. Financials (In case of listed companies)
16.5.5. Recent Developments
16.5.6. SWOT Analysis
16.6. Pfizer Inc.
16.6.1. Business Overview
16.6.2. Company Snapshot
16.6.3. Products & Services
16.6.4. Financials (In case of listed companies)
16.6.5. Recent Developments
16.6.6. SWOT Analysis
16.7. Zydus Pharmaceuticals, Inc.
16.7.1. Business Overview
16.7.2. Company Snapshot
16.7.3. Products & Services
16.7.4. Financials (In case of listed companies)
16.7.5. Recent Developments
16.7.6. SWOT Analysis
16.8. Lupin Pharmaceuticals, Inc.,
16.8.1. Business Overview
16.8.2. Company Snapshot
16.8.3. Products & Services
16.8.4. Financials (In case of listed companies)
16.8.5. Recent Developments
16.8.6. SWOT Analysis
16.9. Amneal Pharmaceuticals LLC.
16.9.1. Business Overview
16.9.2. Company Snapshot
16.9.3. Products & Services
16.9.4. Financials (In case of listed companies)
16.9.5. Recent Developments
16.9.6. SWOT Analysis
16.10.Teva Pharmaceutical industries Ltd.
16.10.1. Business Overview
16.10.2. Company Snapshot
16.10.3. Products & Services
16.10.4. Financials (In case of listed companies)
16.10.5. Recent Developments
16.10.6. SWOT Analysis
17. Strategic Recommendations
18. About Us & Disclaimer